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Background: Although single- and paired-pulse (sp/pp) transcranial magnetic stimulation
(TMS) studies are considered minimal risk in adults and children, the safety profile for
theta-burst TMS (TBS) is unknown.
Objective: In this comparative analysis, we explored the rate, severity, and specific
symptoms of TMS-related adverse effects (AEs) between sp/ppTMS and TBS in subjects
between ages 6 and 18 years.
Method: Data from 165 participants from 2009 to 2014 were analyzed. Assessment of
AEs was performed based on baseline and post-TMS administration of a symptom-based
questionnaire that rated AEs on a 5-level ordinal scale (minimal, mild, moderate, marked,
severe). AE rates and severity were compared using Chi Square or Fisher’s Exact Test
depending on data characteristics.
Result: Overall, no seizures or severe-rated AEs were reported by 165 pediatric
participants. The rate of AE in all TBS sessions was 10.5% (n = 76, 95% CI: 4.7–19.7%),
whereas the rate of AE in all sp/ppTMS sessions was 12.4% (n = 89, 95% CI: 6.3–21.0%).
There was no statistical difference in AE rates between TBS and sp/ppTMS (p = 0.71). In
all sp/ppTMS and TBS sessions, 20 subjects reported a total of 35 AEs, among these 31
(∼88.6%) were rated as “minimal” or “mild”. There was no difference in the severity of
AE between TBS and sp/ppTMS (p = 1.0). Only one of 76 TBS participants reported an AE
rated as more than minimal/mild.
Conclusion: Our comparative analysis showed that TBS appears to be as safe as
sp/ppTMS in terms of AE rate and severity. This report supports further investigation of
TBS in children.
Keywords: children, youth, transcranial magnetic stimulation, repetitive transcranial magnetic stimulation, theta
burst stimulation, safety
INTRODUCTION
Transcranial magnetic stimulation (TMS) is a non-invasive form
of brain stimulation that has been increasingly used to develop
physiological biomarkers and in therapeutic applications of
neurological and psychiatric conditions across a wide range of
subjects. Currently, consensus guidelines have suggested that
single- and paired-pulse TMS (sp/ppTMS) may be considered
as minimal risk in children (Gilbert et al., 2004; Rossi et al.,
2009). In contrast, repetitive TMS (rTMS) which may include
rapid trains of TMS pulses do not have clear guidelines for
use in the pediatric population and carry a potential risk
of epileptogenesis (Oberman and Pascual-Leone, 2009). Theta
Burst Stimulation (TBS), a type of rTMS, can induce effects
on cortical excitability that outlast the stimulation period
(Huang et al., 2005). Although TBS and conventional rTMS
have been shown to elicit comparable cortical neurophysiologic
changes (Zafar et al., 2008; Di Lazzaro et al., 2011), the TBS
procedure has two advantages: (1) shorter stimulation duration;
and (2) lower stimulation intensity. These features decrease
the likelihood of discomfort from TMS pulses, thus making
TBS a potentially ideal rTMS protocol to use in pediatric
studies.
Several systematic reviews have suggested that TBS is relatively
well-tolerated in the adult population including two recent
studies that have estimated an approximately 5% rate of adverse
events of adults undergoing TBS, which are primarily mild
(Oberman et al., 2011; Maizey et al., 2013). To our knowledge,
only one serious adverse event (AE), seizure, was reported in
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a healthy adult male during continuous TBS performed at
100% of resting motor threshold (RMT; Oberman and Pascual-
Leone, 2009). In children, we recently reported a total AE
rate of 11.6% in 40 children undergoing TBS (Wu et al.,
2012).
Future applications of TBS in children as a biomarker or as
a therapeutic modality are contingent on a clearer estimate of
potential risks of adverse events including sharing sensitive safety
data between laboratories (Rossi et al., 2009). In the present
report, we compare AE rates between TBS and sp/ppTMS in a
cohort of youth over a five year period in a TMS lab within a
large stand-alone children’s hospital. We additionally explored
the incidence of adverse events across protocol parameters and
examined predictors of adverse events.
MATERIALS AND METHODS
PARTICIPANTS
Data from 165 unique participants (69 females, 96 males)
between ages 6–18 years were analyzed from Institutional
Review Board (IRB)-approved protocols which were active
in our TMS Lab between 2009 and 2014. Subjects with
epilepsy, hearing problems, serious medical condition(s), or
implanted medical device(s) were excluded from participation.
Recruitment occurred through sub-specialty clinics, hospital
wide emails, and from the community. Safety data for TBS
was drawn from two studies: (1) TBS technique optimization
and biomarker studies which involved healthy and Tourette
Syndrome (TS) youths; and (2) a sham-controlled continuous
TBS study in TS (Wu et al., 2014). Sp/ppTMS safety data was
summarized from studies involving youth with attention deficit
hyperactivity disorder (ADHD) and typically developed controls.
For the sp/ppTMS studies, ADHD subjects on non-stimulant
medications (e.g., atomoxetine) were excluded and those on
stimulants were instructed to hold the medication for at least
24 h prior to participation. None of the typically developed
controls were on any neuropsychiatric medications at the time
of participation. All parent(s)/guardian(s) gave written informed
consent for the studies.
TRANSCRANIAL MAGNETIC STIMULATION
Sp/ppTMS was performed with a Magstim 200/Bistim stimulator
and a 70 mm figure-8 coil (Magstim Co., Wales, UK). Surface
electromyography (EMG) leads were placed over the dominant
first dorsal interosseous (FDI) muscle. The coil was placed over
the dominant primary motor cortex at the optimal site for
obtaining a motor-evoked potential (MEP). RMT and active
motor thresholds, cortical silent period, and single and paired
pulse amplitudes and ratios were quantified using standard
methods, requiring approximately 200 TMS pulses (Rossini
et al., 1994; Mills and Nithi, 1997). In paired pulse TMS
studies, the intensities of the conditioning and test pulses were
predetermined and set at 60% and 120% of RMT respectively.
TBS was performed with Magstim SuperRapid2 (Magstim Co.,
Wales, UK). TBS stimulation intensities ranged from 60–90%
RMT. Three pulses were administered at 30 to 50 Hz pulse
frequency, 5 Hz burst frequency, with a total number of
pulses of either 300 or 600 (Huang et al., 2005). TBS was
preceded and followed by spTMS used for post-TBS MEP
measurement. This required approximately 200 spTMS pulses.
Nine participants received both intermittent and continuous TBS
(iTBS, cTBS). TBS administration for the sham controlled trial
(Wu et al., 2014) did not involve post TBS assessment of MEP
amplitudes.
ASSESSMENT OF ADVERSE EVENTS
A sixteen-question review of systems (ROS) questionnaire was
administered to rate the subjective symptom (headache, scalp
pain, arm/hand pain, other pain(s), numbness/tingling, other
sensation(s), weakness, loss of dexterity, vision/hearing change(s),
ear ringing, nausea/vomiting, appetite loss, rash, skin change(s)
or any other symptom(s)) on a scale of 0 to 5 (none, minimal,
mild, moderate, marked, severe) prior to any TMS application. At
the end of the study after the entire TMS session, this ROS was
repeated to detect any AE. The presence of an AE was defined as
a positive increase in any of the ROS criteria compared to pre-
TMS. The rate of AE was defined as the ratio of sessions with
adverse events divided by total sessions. In the Tourette Syndrome
study (Wu et al., 2014), patients received two consecutive days
of real or sham TBS. Only day 1 AEs were used for data
analysis.
STATISTICAL ANALYSIS
T-test or Wilcoxon Mann Whitney test was used to compare
demographics depending on data distribution. Comparison of
AE rates were analyzed using either Chi Square or Fisher’s
Exact Test depending on whether any cell of the 2 × 2
table has a count <5. All types of TBS were combined
into one group. TS, ADHD, and other motor disorder
were considered “affected”. Logistic regression analyses were
used to estimate effects of additional predictors. Analyses
including power calculations were performed using SAS v9.3
(Cary, NC).
RESULTS
DEMOGRAPHICS
Demographics and clinical data are shown in Table 1. Among 76
children receiving TBS, 68% were typically developing healthy
controls, 25% had a diagnosis of TS, or 7% had other motor
disorders. Among 89 participants receiving sp/ppTMS, 21%
participants were healthy controls, and 79% participants were
affected with ADHD. Of the 24 TBS participants with either TS or
other motor disorders, 15 of them were taking neuropsychiatric
medications at the time of the TMS session. Collectively, these
medications included amitriptyline, atomoxetine, baclofen,
citalopram, clonidine, dexmethylphenidate, escitalopram,
guanfacine, melatonin, methylphenidate, pimozide, quetiapine,
risperidone and sertraline.
ADVERSE EVENT RATES
AE rates are shown in Table 2. All participants completed
sp/ppTMS or TBS sessions without seizures and there were no
serious adverse events. There was no statistical difference in AE
rates between sp/ppTMS and TBS sessions (p = 0.71). There was
no difference in frequency of AE between sham and real TBS in
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Table 1 | All participant characteristics and adverse events.
Participant characteristics TBS protocols (n = 76) Sp/ppTMS protocols (n = 89) p-value
Age, mean (SD) 12.3 (2.9) 10.3 (2.5) <0.0001
Sex (% male) 57.9% 58.4% 0.63
Diagnosis (% control) 68.4% 21.3% <0.0001
% Sessions with adverse events (95% CI) 10.5% (4.7–19.7%) 12.4% (6.3–21.0%) 0.71
CI = confidence interval, SD = standard deviation, TBS = Theta Burst Stimulation, Sp/ppTMS = single and paired pulse transcranial magnetic stimulation.
the clinical trial. The AE rates were not statistically significant (p
= 1.0) between cTBS-only (12.5%, n = 8) and iTBS-only sessions
(11.9%; n = 59).
SEVERITY AND SPECIFIC SYMPTOMS
In TBS sessions, no “marked” or “severe” symptoms were
reported. Of thirteen post-TBS AEs, twelve (92.3%) were rated
“minimal’ or “mild” with one described as “moderate”. There
were twenty-two post-sp/ppTMS AEs: twenty (90.9%) were rated
“minimal” or “mild” and two were “moderate” or “marked”.
Proportions of minimal/mild AEs did not differ between TBS
and sp/ppTMS (p = 1.0). Specific symptoms were comparable
(Table 2).
ADVERSE EVENT RATES: HEALTHY VS. AFFECTED CHILDREN
Healthy control participants reported AEs in 11.5% of TBS vs.
5.3% of sp/ppTMS sessions (p = 0.67) (Table 3). Children with
neurological diagnoses reported AEs in 8.3% of TBS vs. 14.3% of
sp/ppTMS sessions (p = 0.72).
ADVERSE EVENT RATES: SHAM VS. ACTIVE TBS
In a small sample of participants who received either active or
sham cTBS (Wu et al., 2014), no difference was detected between
sham vs. active TBS (p = 1.0).
Table 2 | Percentages of participants experiencing specific adverse
events.
Symptom TBS (n = 76) Sp/ppTMS (n = 89)
Headache 6.6% 6.7%
Scalp pain – 4.5%
Arm/hand/other pain 2.6%∗ 2.2%
Numbness/tingling 2.6% 5.6%
Other sensations 2.6% 1.1%∗∗
Weakness 1.3% –
Ringing in ears – 1.1%∗
Nausea/vomiting – 1.1%
Other 1.3% 1.1%
All adverse events were rated minimal to mild except: *one subject each rated
“moderate”; **one subject rated “marked”. “Other sensations**” referred to
chest pain that was present at baseline due to one subject having an upper
respiratory infection at the time of the visit. The “ringing in ears*” and “other
sensations**” ratings were from the same individual within one sp/ppTMS
session. TBS = Theta Burst Stimulation, Sp/ppTMS = single and paired pulse
transcranial magnetic stimulation.
PREDICTORS OF AEs
No predictors of the odds of an AE were identified after data
relating to all participants (Age, Sex, Diagnosis, RMT, mode of
TMS) were entered into a backward logistic regression analysis.
DISCUSSION
In this brief report, we found no greater rate of adverse events
of TBS compared to sp/ppTMS in a large cohort of pediatric
subjects. The majority of AEs reported were classified minimal
or mild with no severe or serious AE such as seizure. Headache
was the most commonly reported specific AE in both groups.
These findings represent the largest published sample analyzed
to address an important gap in the safety literature regarding
youth who have underwent TBS and contribute to other safety
studies of TBS (Oberman et al., 2011; Wu et al., 2012; Maizey
et al., 2013). The findings of this study are reassuring with
regards of continued judicious use of similar TBS methods in
youth.
The purpose of comparing TBS-induced AE rates to that
of sp/ppTMS is because single and paired-pulse stimulations
have been suggested to be “minimal risk” in children (Gilbert
et al., 2004). The most recent international TMS Consensus
Group “cautiously conclude that single-pulse and paired-pulse
TMS in pediatrics is safe for children two years and older
(Rossi et al., 2009)”. However, not all local IRB or ethics
boards may agree with this statement. In the Code of Federal
Regulations Section 46.102 of the United States of America,
Minimal Risk means that the “probability and magnitude of
harm or discomfort anticipated in the research are not greater
in and of themselves than those ordinarily encountered in
daily life or during the performance of routine physical or
psychological examination or tests”. According to this definition,
sp/ppTMS may be considered as Minimal Risk for the following
reasons. First, children have rated the sp/ppTMS experience
more enjoyable than several common life events (long car
ride, throwing up, go to dentist, shot at the doctor’s) (Garvey
et al., 2001). Second, like other medical tests commonly used in
pediatric patients (e.g., brain MRI, computer tomography, nerve
conduction study and EMG), TMS delivers “energy” into the
human body. Contrarily, one can certainly argue that healthy
children would not otherwise receive any of these medical tests
and therefore TMS participation might constitute greater than
minimal risk. Ultimately when working with the IRB/ethics board
in developing any pediatric TMS (sp/pp or rTMS) study, it
is critical to concisely present the TMS technology, scientific
background/rationale, screening procedure (Rossi et al., 2011)
and safety monitoring (Rossi et al., 2009; Krishnan et al., 2015)
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Table 3 | Healthy control participant characteristics and adverse events.
Participant characteristics TBS protocols (n = 52) Sp/ppTMS protocols (n = 19) p-value
Age, mean (SD) 12.6 (2.8) 12.1 (3.2) 0.44
Sex (% male) 51.9% 47.4% 0.79
% Sessions with adverse events (95% CI) 11.5% (4.4–23.4%) 5.3% (0.13–26.0%) 0.67
CI = confidence interval, SD = standard deviation, TBS = Theta Burst Stimulation, Sp/ppTMS = single and paired pulse transcranial magnetic stimulation.
for the proposed study. As more pediatric TMS safety data
emerges, it may become easier for investigators and IRB/ethical
boards to objectively decide whether the proposed study is safe to
proceed.
The two primary limitations of the study are sample size, and
the timing of AE assessments after both sp/ppTMS and TBS in
TBS protocols. Verifying small differences in rates of AEs may
not be feasible without much larger samples. Using our data,
we estimate approximately 4,400 children would be needed per a
group to have an 80% power to detect this ∼2% difference using
an alpha of 0.05. AE assessments at the end of the session captured
added spTMS plus TBS effects as participants also received spTMS
for TBS sessions. Our finding of comparable AE rates thus
suggests that the majority of AEs in TBS sessions occurred may be
due to spTMS. This is further supported by findings in the sham-
controlled study (Wu et al., 2014) which, consistent with the adult
data (Maizey et al., 2013), were equivalent in the true and sham
TBS arms. While the AE rates may also have been influenced by
differences in age and case mix, the negative regression analysis
suggests these effects were, at most, small. Another significant
limitation is that we pooled the safety data from several studies
over a five year period. Therefore, this analysis represents a
heterogeneous group, including typically developing youth as well
as affected pediatric population across different TMS protocols.
Only one of our studies in this time period employed a sham TBS
stimulation, therefore, we analyzed the data separately. Although
we did not detect a difference in the sham vs. active TBS AE
rates, this analysis is limited by the small sample size (n = 10)
(Wu et al., 2014). Due to the same issue of small sample size,
another concern that cannot be fully addressed in this report
is the effect(s) of concurrent neuropsychiatric medication(s) on
TBS safety. At the time of TBS sessions, fifteen participants
were actively taking neuropsychiatric medications, some of which
are known to lower seizure threshold (Pisani et al., 2002) and
change cortical excitability (Ziemann et al., 2014). Given that
some children were on medications that can potentially lower
seizure threshold, it is encouraging that no one developed any
TBS-induced seizures. Finally, the epilepsy exclusionary criterion
is a limiting factor. Although available data suggests that seizure
induction during rTMS for epilepsy patients is relatively low,
most of the data are from adult populations (Bae et al., 2007).
As TMS is increasingly used in epilepsy research, the risk of
seizure provocation by various forms of rTMS, including TBS,
in children with epilepsy is a knowledge gap that needs to be
addressed.
TBS and other forms of rTMS hold promise for future
pediatric neurophysiologic studies (Oberman et al., 2010, 2014;
Damji et al., 2013) and clinical trials (Kirton et al., 2008; Wu et al.,
2014). With comprehensive ongoing safety monitoring, published
frequencies, and subthreshold intensities, further investigation of
TBS within previously reported parameters in children appears to
confer no greater risk than single and paired-pulse TMS.
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